

August 8, 2012

To,
The Manager (Listing),
National Stock Exchange of India Ltd.,
"Exchange Plaza", G-1, Block G,
Bandra-Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir;

Re: Press Release - Product development and license agreement with
Accu-Break pharmaceuticals, Inc, USA.

With reference to the captioned matter, we enclose herewith a Press Release
dated August 8, 2012 captioned Alembic Pharmaceuticals Limited enters into
Product development and license agreement with Accu-Break pharmaceuticals,
Inc, USA

Kindly take note of the same.

Thanking you,


Yours faithfully,
For **Alembic Pharmaceuticals Limited**

R.K. Baheti
Director-Finance &
Company Secretary

Encl: A/a

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA TEL : (0265) 2280550, 2280880, 3053333 FAX : (0265) 2284729
www.alembic-india.com E-mail : hrd@alembic.co.in

**PRESS RELEASE****Date: August 8, 2012****Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break pharmaceuticals, Inc, USA.**

Alembic Pharmaceuticals Limited announced today that they have entered into a development and license agreement with Accu-Break Pharmaceuticals, Inc, USA ("ABP") to develop new brand products that will use ABP's innovative Accu-Break™ tablet technologies. ABP's patented Accu-Break tablets can be split easily by hand into exact smaller doses to provide maximum flexibility, and to make it easier and safer for patients and caregivers to adjust their dosage. The first product that ABP will seek Food and Drug Administration marketing approval for is an Accu-Break-formatted version of the popular anticoagulant medication warfarin.

About Alembic:

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 3000 sales representatives, are well recognized by doctors and patients. More information about the company can be found at www.alembic-india.com; (Reuters: ALEM.NS, Bloomberg: ALPM: IN, NSE: APLLTD, BSE: 533573)

About Accu-Break Pharmaceuticals, Inc:

Based in Plantation, Florida, ABP is a technology licensing and product development company. ABP has invented, developed and patented a suite of novel Accu-Break™ technologies that enable pharmaceutical tablets to be made that can be subdivided by hand into accurate partial doses with the intent of making it easier and safer for patients to adjust their dose. Behind the strength of its innovative inventions and broad patent portfolio, the Company is currently developing its first product, and is licensing the Accu-Break technologies to other parties for product development. ABP currently has 48 patents issued and 22 patents pending worldwide. For more information please visit www.accubreak.com.

For further information:

Mitanshu Shah
Phone: +91 265 3007630
Email: mitanshu.shah@alembic.co.in